Arvinas to Present at Jefferies Healthcare Conference Amid Key Strategic Moves
Event summary
- Arvinas will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:55 a.m. ET.
- The company recently secured FDA approval for its first PROTAC drug, VEPPANU, in partnership with Pfizer.
- Arvinas is negotiating a transaction with Rigel Pharmaceuticals for global rights to VEPPANU, pending regulatory approvals.
- Arvinas has multiple investigational drugs in clinical development, targeting neurodegenerative disorders, cancers, and rare diseases.
The big picture
Arvinas' participation in the Jefferies conference comes at a pivotal time, following the FDA approval of its first PROTAC drug and ongoing strategic transactions. The company is positioning itself as a leader in targeted protein degradation, with a growing pipeline of therapies addressing high-unmet medical needs. The success of its partnerships and regulatory milestones will be critical in determining its long-term market position.
What we're watching
- Regulatory Approval
- The pace at which Arvinas and Rigel complete the transaction for VEPPANU, contingent on regulatory approvals.
- Clinical Pipeline
- How Arvinas advances its pipeline of investigational drugs, particularly in neurodegenerative and oncology indications.
- Market Positioning
- Whether Arvinas can leverage its FDA-approved PROTAC to solidify its leadership in targeted protein degradation therapies.
Related topics